BNTC - Benitec Biopharma Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.21
0.00 (0.00%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close3.21
Open3.39
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.21 - 3.39
52 Week Range1.85 - 4.20
Volume768
Avg. Volume13,732
Market Cap31.308M
Beta3.91
PE Ratio (TTM)N/A
EPS (TTM)-0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • ASX/NASDAQ Announcement
    PR Newswire3 days ago

    ASX/NASDAQ Announcement

    NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD).  This update should be read in conjunction with the latest corporate presentation which can be found on the Company's website. The first clinical site has now been opened in Australia and the Company anticipates having additional Australian sites open later this month.  Regulatory review with the Ministry of Health is ongoing in Russia and the Company expects approval at the end of May.

  • PR Newswire2 months ago

    Benitec Biopharma Launches its Phase 2 Oncology Study in Australia

    NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi or 'expressed RNAi', today announced the start of its Phase 2 clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC). The Phase 2 open label study has been designed to explore the safety, tolerability and efficacy of BB-401 following intratumoral injections into the lesions of patients with recurrent or metastatic HNSCC.  The study will enrol up to 30 patients at 5-8 sites across Australia and Russia.  The trial is registered on www.clinicaltrials.gov with the identifier: NCT03433027, where more details can be found.

  • PR Newswire2 months ago

    Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update

    SYDNEY , Feb. 22, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative ...

  • PR Newswire3 months ago

    Federal R&D Tax Credit Received

    SYDNEY , Jan. 23, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $4,112,058 cash refund for the year ended 2017 under the Federal ...

  • PR Newswire3 months ago

    Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy

    NASDAQ: BNTCW) today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD). The Orphan Drug Designation granted to Benitec may provide a range of valuable benefits, including fast track process for clinical regulatory approval, potential extension of patent life with a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.  In short, a clear and expeditious path for cost-efficient development and commercialisation.

  • TheStreet.com5 months ago

    Alkermes Jumps on License Deal With Biogen -- Biotech Movers

    Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

  • PR Newswire5 months ago

    Benitec Biopharma provides update on OPMD orphan disease program

    NASDAQ:BNTCW) is pleased to announce it has submitted an application with the U.S. Food & Drug Administration (FDA) seeking orphan drug designation for BB-301 as a treatment of oculopharyngeal muscular dystrophy (OPMD). BB-301 is a single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with OPMD, while simultaneously adding back a copy of the normal version of the same gene to restore gene function. To receive orphan drug designation from the FDA, a company must demonstrate that the condition addressed by the drug or biologic affects less than 200,000 persons in the U.S.  The company must also provide the FDA with sufficient information to establish a medically plausible basis for expecting the product will be an effective treatment.

  • PR Newswire6 months ago

    U.S. patent granted for Benitec hepatitis B program

    SYDNEY , Oct. 18, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued ...

  • Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017
    Capital Cube8 months ago

    Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Benitec Biopharma Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Benitec Biopharma Ltd. – Ionis Pharmaceuticals, Inc. and Affimed N.V. (IONS-US and AFMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.12 million, ... Read more (Read more...)

  • PR Newswire9 months ago

    Benitec Biopharma advances OPMD orphan disease program

    NASDAQ: BNTCW) is pleased to announce it has developed a new single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with oculopharyngeal muscular dystrophy (OPMD), while simultaneously adding back a copy of the normal version of the same gene to restore gene function.  This next generation single vector system, termed BB-301, represents the clinical candidate that Benitec intends to advance into human clinical trials in the second half of calendar year 2018.